We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
-12.49%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$48.6B
AUM Growth
-$4.2B
(-8%)
Cap. Flow
+$3.6B
Cap. Flow
% of AUM
7.4%
Top 10 Holdings %
Top 10 Hldgs %
10.29%
Holding
4,108
New
835
Increased
964
Reduced
740
Closed
743
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$340M |
| 2 |
Bank of America
BAC
|
+$302M |
| 3 |
Cigna
CI
|
+$294M |
| 4 |
TSMC
TSM
|
+$275M |
| 5 |
Union Pacific
UNP
|
+$256M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$426M |
| 2 |
S&P Global
SPGI
|
+$413M |
| 3 |
Booking.com
BKNG
|
+$264M |
| 4 |
Comcast
CMCSA
|
+$256M |
| 5 |
Teleflex
TFX
|
+$241M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Financials | 16.96% |
| 3 | Technology | 16.37% |
| 4 | Consumer Discretionary | 9.33% |
| 5 | Industrials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3101
Castle Biosciences
CSTL
$749M
| $228K | ﹤0.01% |
+10,400
| New | +$242K |
|
3102
IDEX
IEX
$16.5B
| $227K | ﹤0.01% |
1,257
-26,521
| -95% | -$5M |
|
|
REFI
3103
Chicago Atlantic Real Estate Finance
REFI
$258M
| $227K | ﹤0.01% |
15,098
-13,256
| -47% | -$223K |
|
3104
Wayfair
W
$11.1B
| $227K | ﹤0.01% |
+5,203
| New | +$366K |
|
|
TCDA
3105
DELISTED
Tricida, Inc. Common Stock
TCDA
| $227K | ﹤0.01% |
23,429
-64,485
| -73% | -$614K |
|
|
GBIO
3106
DELISTED
Generation Bio
GBIO
| $226K | ﹤0.01% |
3,447
| – | – |
|
3107
Pulmonx
LUNG
$49.4M
| $226K | ﹤0.01% |
+15,341
| New | +$316K |
|
3108
Syndax Pharmaceuticals
SNDX
$1.84B
| $224K | ﹤0.01% |
11,637
-97,981
| -89% | -$1.63M |
|
3109
PUT
Invesco CurrencyShares British Pound Sterling Trust
FXB
$76.9M
| $223K | ﹤0.01% |
+1,900
| New | +$229K |
|
|
ZY
3110
DELISTED
Zymergen Inc. Common Stock
ZY
| $223K | ﹤0.01% |
+181,580
| New | +$304K |
|
3111
Montauk Renewables
MNTK
$266M
| $222K | ﹤0.01% |
+22,100
| New | +$263K |
|
3112
Xometry
XMTR
$4.77B
| $222K | ﹤0.01% |
6,557
-270,244
| -98% | -$9.32M |
|
|
MOMO
3113
Hello Group
MOMO
$869M
| $221K | ﹤0.01% |
+43,675
| New | +$229K |
|
3114
Clearwater Paper
CLW
$271M
| $220K | ﹤0.01% |
+6,543
| New | +$205K |
|
|
EMAN
3115
DELISTED
eMagin Corporation
EMAN
| $219K | ﹤0.01% |
335,103
| – | – |
|
|
BGRY
3116
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $218K | ﹤0.01% |
150,000
| – | – |
|
3117
Array Technologies
ARRY
$818M
| $217K | ﹤0.01% |
+19,618
| New | +$194K |
|
3118
Leidos
LDOS
$14.1B
| $217K | ﹤0.01% |
+2,157
| New | +$224K |
|
3119
PUT
Qualcomm
QCOM
$176B
| $217K | ﹤0.01% |
1,700
-2,500
| -60% | -$339K |
|
3120
SkinHealth Systems
SKIN
$94.9M
| $217K | ﹤0.01% |
16,800
-1,249,085
| -99% | -$16.7M |
|
3121
Deere & Co
DE
$170B
| $215K | ﹤0.01% |
717
-7,402
| -91% | -$2.73M |
|
|
APEN
3122
DELISTED
Apollo Endosurgery, Inc.
APEN
| $215K | ﹤0.01% |
58,923
-18,503
| -24% | -$87.5K |
|
3123
Mirum Pharmaceuticals
MIRM
$6.89B
| $214K | ﹤0.01% |
+10,960
| New | +$259K |
|
|
SKYAW
3124
CALL
DELISTED
Skydeck Acquisition Corp. Warrants
SKYAW
| $214K | ﹤0.01% |
21,933
| – | – |
|
3125
Adtran
ADTN
$798M
| $213K | ﹤0.01% |
+12,227
| New | +$221K |
|
Similar funds
Marshall Wace's Q2 2022 Portfolio in Review
As of Q2 2022, Marshall Wace held 4,108 positions worth $48.6B, down 8% from $52.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Marshall Wace deployed $3.6B of net new capital in Q2 2022, opening 835 new positions and adding to 964 existing holdings. Its largest new stake was Eli Lilly: 1,133,393 shares worth $367M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Verizon, an estimated $426M trimmed.
- Marshall Wace's largest Q2 2022 buy was Eli Lilly: 1,133,393 shares worth $367M.
- Marshall Wace added most to Bank of America in Q2 2022, an estimated $302M increase.
- Marshall Wace's biggest Q2 2022 reduction was Verizon, cutting an estimated $426M.
- Marshall Wace fully exited Teleflex in Q2 2022, selling an estimated $241M.
- Marshall Wace's ten largest holdings make up 10% of its $48.6B portfolio in Q2 2022.
- Marshall Wace opened 835 new positions and closed 743 in Q2 2022.
- Marshall Wace's portfolio value fell 8% quarter-over-quarter to $48.6B.
Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.